慢性丙型肝炎肝外疾病研究进展

肝脏 ›› 2023, Vol. 28 ›› Issue (3): 370-373.

慢性丙型肝炎肝外疾病研究进展

豆文丽, 贺娜, 田亚文, 郝帅, 赵梓棋, 孔繁娇, 任晫煦, 罗羽杉, 闫红林

710003 陕西西安医学院(豆文丽);西安医学院第一附属医院(豆文丽,贺娜,田亚文,郝帅,赵梓棋,孔繁娇,任晫煦,罗羽杉,闫红林)

收稿日期:2022-06-29 出版日期:2023-03-31 发布日期:2023-08-28
通讯作者: 闫红林,Email:Yanhonglin666@163.com
基金资助:
西安医学院大学生创新创业训练计划项目(202111840012);佑安肝病传染病专科医疗联盟专项基金(LM202003);陕西省教育科学“十三五”规划课题(SGH20Y1330)

Received:2022-06-29 Online:2023-03-31 Published:2023-08-28

摘要/Abstract

摘要： 随着直接抗病毒时代的到来,持续的病毒应答(SVR)可以以近100%的速度实现,丙型病毒性肝炎的治疗已不再是关注的重点问题。然而,丙型病毒性肝炎相关病死率仍然在逐年上升,其原因之一是丙型病毒性肝炎肝外疾病同样也会影响患者疾病的进展及病死率,说明病毒清除并不能完全缓解肝外表现。所以本文旨在阐述丙肝的肝外疾病,加强对丙肝的全面认识,有助于对丙肝患者病毒清除后的进一步诊治提供参考。

豆文丽, 贺娜, 田亚文, 郝帅, 赵梓棋, 孔繁娇, 任晫煦, 罗羽杉, 闫红林. 慢性丙型肝炎肝外疾病研究进展[J]. 肝脏, 2023, 28(3): 370-373.

[1] 中华医学会健康管理学分会,中华医学会肝病学分会, 中华医学会检验医学分会. 病毒性肝炎健康管理专家共识 ( 2021年). 中华健康管理学杂志,2021,15(4): 323-331.
[2] Kuna L, Jakab J, Smolic R, et al. HCV extrahepatic manifestations. J Clin Transl Hepatol, 2019,7(2):172-182.
[3] Hum J, Jou JH, Green PK, et al.Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus. Diabetes Care, 2017,40(9):1173-1180.
[4] Wong AH,Sie J,Chen A,et al. Glycemic control after initiating direct-acting antiviral agents in patients with hepatitis C virus and type 2 diabetes mellitus using the united states integrated healthcare system. J Res Pharm Pract, 2020,9(1):16-23.
[5] Younossi Z, Park H, Henry L, et al.Extrahepatic manifestations of hepatitis C: A meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology, 2016,150(7):1599-1608.
[6] Abenavoli L, Masarone M, Peta V, et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol, 2014,20(41):15233-15240.
[7] 郑双, 李异玲. 代谢相关脂肪性肝病和慢性丙型病毒性肝炎的相关性研究进展.中国综合临床,2021,37(2):180-184.
[8] Cheng CH, Chu CY, Chen HL, et al.Virus elimination by direct-acting antiviral agents impacts glucose homeostasis in chronic hepatitis C patients. Front Endocrinol (Lausanne), 2022,12:799382.
[9] Adinolfi LE, Petta S, Fracanzani AL, et al.Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. Atherosclerosis, 2020,296:40-47.
[10] Adinolfi LE, Nevola R, Guerrera B, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol, 2018,33(7):1379-1382.
[11] Cheng YT, Cheng JS, Lin CH, et al.Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective study. Clin Microbiol Infect, 2020,26(3):366-372.
[12] Chang ML, Hu JH, Chen WT, et al. Interactive impacts from hepatitis C virus infection and mixed cryoglobulinemia on complement levels. Dig Dis Sci, 2021,66(7):2407-2416.
[13] Desbois AC, Cacoub P, Saadoun D. Cryoglobulinemia: An update in 2019. Joint Bone Spine, 2019,86(6):707-713.
[14] Bhandari J, Awais M, Aeddula NR. Cryoglobulinemia. Treasure island (FL): StatPearls Publishing,2022,PMID: 32491538.
[15] Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia vasculitis. Am J Med, 2015,128(9):950-955.
[16] Michot JM, Canioni D, Driss H, et al.Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol, 2015,90(3):197-203.
[17] Monti G, Pioltelli P, Saccardo F,et al.Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med, 2005,165(1):101-105.
[18] Alkrekshi A, Kassem A, Park C, et al. Risk of non-hodgkin's lymphoma in hcv patients in the United States between 2013 and 2020: A population-based study. Clin Lymphoma Myeloma Leuk, 2021,21(11):e832-e838.
[19] Peveling-Oberhag J, Arcaini L, Hansmann ML, et al.Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol, 2013,59(1):169-177.
[20] Rattotti S, Ferretti VV, Rusconi C,et al.Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the rete ematologica lombarda (REL) clinical network. Hematol Oncol, 2019,37(2):160-167.
[21] Visco C, Wang J, Tisi MC, et al.Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. Br J Cancer, 2017,117(11):1685-1688.
[22] Fabrizi F, Plaisier E, Saadoun D, et al.Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis, 2013,61(4):623-637.
[23] Roth D, Nelson DR, Bruchfeld A,et al.Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet, 2015,386(10003):1537-1545.
[24] Stine JG, Cornella S, Shah NL. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir,Ann Rheum Dis, 2015,74(11):2102.
[25] Bailey AL, Al-Adwan S, Sneij E, et al.Atherosclerotic cardiovascular disease in individuals with hepatitis C viral infection. Curr Cardiol Rep, 2021,23(5):52.
[26] Adinolfi LE, Restivo L, Zampino R, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis, 2012,221(2):496-502.
[27] Nevola R, Acierno C, Pafundi PC, et al. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. Minerva Med, 2021,112(2):188-200.
[28] Ferri C, Ramos-Casals M, Zignego AL, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev, 2016,15(12):1145-1160.
[29] Lee K, Otgonsuren M, Younoszai Z,et al. Association of chronic liver disease with depression: a population-based study. Psychosomatics, 2013,54(1):52-59.
[30] Aregay A, Dirks M, Schlaphoff V, et al. Systemic inflammation and immune cell phenotypes are associated with neuro-psychiatric symptoms in patients with chronic inflammatory liver diseases. Liver Int, 2018,38(12):2317-2328.
[31] Yoon MS, Obermann M, Dockweiler C, et al. Sensory neuropathy in patients with cryoglobulin negative hepatitis-C infection. J Neurol, 2011,258(1):80-88.
[32] Authier FJ, Bassez G, Payan C, et al. Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy. Neurology, 2003,60(5):808-812.
[33] Fabrazzo M, Zampino R, Vitrone M, et al. Effects of direct-acting antiviral agents on the mental health of patients with chronic hepatitis C: A prospective observational study. Brain Sci, 2020,10(8):483.
[34] Gallach M, Vergara M, Pedro da Costa J,et al. Correction: Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. PLoS One, 2020,15(10):e0241559.

慢性丙型肝炎肝外疾病研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	郭峰, 窦婧, 徐强, 王晓波, 马燕, 乐永红, 胡西百合提, 王转国, 王宏峰, 王晓忠. 以索磷布韦为基础的DAA治疗泛基因型慢性丙型肝炎患者的疗效观察[J]. 肝脏, 2021, 26(11): 1224-1227.
[2]	陈学兵, 欧世梅, 刘建英, 刘舒舒, 王秀. 四川德阳地区丙型肝炎病毒基因型分布特征[J]. 肝脏, 2020, 25(12): 1306-1308.